Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases.

Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases.

Opis bibliograficzny
Główni autorzy:	Feldman, M, Taylor, P, Paleolog, E, Brennan, F, Maini, R
Format:	Journal article
Język:	English
Wydane:	1998

Podobne zapisy

Anti-tumor necrosis factor alpha therapy of rheumatoid arthritis. Mechanism of action.
od: Feldmann, M, i wsp.
Wydane: (1997)

TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy.
od: Maini, R, i wsp.
Wydane: (1993)

TNF alpha--a pivotal role in rheumatoid arthritis?
od: Brennan, F, i wsp.
Wydane: (1992)

Targeting TNF alpha for the therapy of rheumatoid arthritis.
od: Maini, R, i wsp.
Wydane: (1994)

Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease.
od: Maini, R, i wsp.
Wydane: (1995)

The role of TNF alpha and IL-1 in rheumatoid arthritis.
od: Feldmann, M, i wsp.
Wydane: (2001)

Insights into the pathogenesis of rheumatoid arthritis from application of anti-TNF therapy.
od: Maini, R, i wsp.
Wydane: (2000)

TNF alpha is an effective therapeutic target for rheumatoid arthritis.
od: Feldmann, M, i wsp.
Wydane: (1995)

TNF alpha as a therapeutic target in rheumatoid arthritis.
od: Feldmann, M, i wsp.
Wydane: (1994)

Evaluation of the role of cytokines in autoimmune disease: the importance of TNF alpha in rheumatoid arthritis.
od: Feldmann, M, i wsp.
Wydane: (1992)

Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases.
od: Taylor, P
Wydane: (2001)

Anti-TNF alpha therapy in rheumatoid arthritis--current and future directions.
od: Taylor, P, i wsp.
Wydane: (2000)

Cytokine expression and networks in rheumatoid arthritis: rationale for anti-TNF alpha antibody therapy and its mechanism of action.
od: Feldmann, M, i wsp.
Wydane: (1995)

TNF alpha blockade in rheumatoid arthritis: rationale, clinical outcomes and mechanisms of action.
od: Elliott, M, i wsp.
Wydane: (1995)

Beneficial effects of tumour necrosis factor-alpha (TNF-alpha) blockade in rheumatoid arthritis (RA)
od: Maini, R, i wsp.
Wydane: (1995)

TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases
od: Feldmann, M, i wsp.
Wydane: (2003)

ANTI TNF THERAPY IN RHEUMATOID ARTHRITIS
od: Feldmann, M, i wsp.
Wydane: (2011)

Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases.
od: Taylor, P
Wydane: (2010)

Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?
od: Feldmann, M, i wsp.
Wydane: (2001)

Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases.
od: Williams, R, i wsp.
Wydane: (2007)

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis.
od: Brennan, F, i wsp.
Wydane: (1989)

From the laboratory to the clinic: Evaluation of cytokines in rheumatoid arthritis highlights TNF-alpha as a new therapeutic target
od: Feldmann, M, i wsp.
Wydane: (1994)

Biology of Inflammation in Crohn's Disease: Mechanisms of Action of Anti-TNF-αAlpha Therapy
od: Stephan R Targan
Wydane: (2000-01-01)

TNFα - A pivotal role in rheumatoid arthritis?
od: Brennan, F, i wsp.
Wydane: (1992)

Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies.
od: Feldmann, M, i wsp.
Wydane: (2002)

Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease?
od: Feldmann, M, i wsp.
Wydane: (2004)

TNF blockade in rheumatoid arthritis: implications for therapy and pathogenesis.
od: Maini, R, i wsp.
Wydane: (1997)

Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases.
od: Feldmann, M, i wsp.
Wydane: (2003)

TNFα blockade in rheumatoid arthritis: Rationale, clinical outcomes and mechanisms of action
od: Elliott, M, i wsp.
Wydane: (1995)

Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis.
od: Paleolog, E, i wsp.
Wydane: (1996)

Malignant melanoma in a patient with Crohn's disease and treated with anti-TNF alpha
od: Alfonso Alcalde Vargas, i wsp.
Wydane: (2013-12-01)

Analysis of the factors related to anti-TNF alpha response in the treatment of Crohn's Disease
od: Carlos Henrique Marques dos Santos
Wydane: (2014-01-01)

A Rare Association of Rheumatoid Arthritis with Crohn’s Disease
od: Hatice Reşorlu, i wsp.
Wydane: (2016-12-01)

Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis.
od: Maini, R, i wsp.
Wydane: (1999)

Cerebral processing of pain in rheumatoid arthritis patients treated with antiTNF-alpha
od: Wartolowska, K, i wsp.
Wydane: (2008)

Intestinal tissue levels of anti-TNF alpha, antibodies, and cytokines in paediatric Crohn disease
od: Vojtech Dotlacil, i wsp.
Wydane: (2025-01-01)

Similar effects of pulse corticosteroid and tumor necrosis factor a blockade in rheumatoid arthritis: Reply
od: Taylor, P, i wsp.
Wydane: (2001)

Selective immunosuppression of tumour necrosis factor-alpha in rheumatoid arthritis.
od: Brennan, F, i wsp.
Wydane: (1995)

Similarities in the mechanisms of action of pulse corticosteroids and anti-tumor necrosis factor alpha therapy in rheumatoid arthritis - Reply
od: Maini, R, i wsp.
Wydane: (1998)

Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis.
od: Charles, P, i wsp.
Wydane: (1999)